Deep Breaths: Updates from CHEST

Dr. Matt Bars is joined by his two colleagues: Dr. Laura Crotty Alexander, Associate Professor of Pulmonary Critical Care Medicine at the University of California San Diego, and Dr. Michael Fiore, Professor of Medicine at the University of Wisconsin and Director of the University of Wisconsin Center for Tobacco Research Intervention. Together, they review tobacco dependence, the CHEST Tobacco Dependence Treatment Toolkit, and resources to help patients.

Supported in part by an independent medical educational grant from Pfizer.

Dr. Matt Bars is joined by his two colleagues: Dr. Laura Crotty Alexander, Associate Professor of Pulmonary Critical Care Medicine at the University of California San Diego, and Dr. Michael Fiore, Professor of Medicine at the University of Wisconsin and Director of the University of Wisconsin Center for Tobacco Research Intervention. Together, they review tobacco dependence, the CHEST Tobacco Dependence Treatment Toolkit, and resources to help patients.

Supported in part by an independent medical educational grant from Pfizer.

About 10 percent of all cancer patients develop treatment-related pulmonary complications, and for lung cancer patients, that risk is even greater. Dr. Gerard Silvestri sits down with Dr. Lynn Tanoue, Professor of Medicine and Vice Chair of Clinical Affairs in the section of pulmonary critical care and sleep medicine at the Yale Cancer Center in New Haven, Connecticut, to discuss pulmonary toxicities related to lung cancer treatment.

An educational campaign brought to you by CHEST, in collaboration with AstraZeneca.

Clinicians can uncover a wealth of information from a non-small cell lung cancer patient’s collected tissue that can help inform treatment decisions. To dive into this idea further, Dr. Gerard Silvestri is joined by his colleague Dr. Michael Machuzak, Full Staff Member in the Department of Pulmonary, Allergy, and Critical Care Medicine at Cleveland Clinic. Together they review the importance of tissue acquisition, proper handling of specimens, rapid onsite evaluation during EBUS-TBNA procedures, and much more.

An educational campaign brought to you by CHEST, in collaboration with AstraZeneca.

Dr. Gerard Sylvestri, the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina in Charleston and Dr. Lonny Yarmus, Clinical Director of the Division of Pulmonary and Critical Care Medicine at Johns Hopkins University, come together to discuss staging in early-stage lung cancer.

An educational campaign brought to you by CHEST, in collaboration with AstraZeneca.

When it comes to managing lung cancer, should we be considering a multidisciplinary approach? Dr. Gerard Sylvestri is joined by Dr. Katie Sears, an assistant professor at the Indiana University School of Medicine, to discuss multidisciplinary lung cancer programs and share suggestions on how to implement this kind of approach.

An educational campaign brought to you by CHEST, in collaboration with AstraZeneca.

Despite widespread availability, only half of Americans received the flu shot last year. With that in mind, Dr. De De Gardner is joined by Dr. Stephanie Briney, Assistant Professor in Family, Community, and Preventive Medicine at the University of Arizona College of Medicine, Phoenix to discuss why Americans avoid getting the flu shot and how she approaches this in her practice.

The prevalence of non-tuberculous mycobacterial (NTM) lung disease in the United States has almost doubled between 2008 and 2015. But despite this increase, its diagnosis can often be delayed, which is why pulmonary nurse practitioner Amy Levinger and Dr. David Griffith join Dr. Tim Aksamit to discuss the diagnostic criteria, tools that can help us make a timely diagnosis of NTM lung disease, and more.

For more information and to access clinician & patient tools about NTM and MAC Lung Disease, click here to visit the CHEST Foundation NTM webpage.

This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.

Up to one-third of asthma cases may be misdiagnosed. Asthma symptoms overlap and can co-exist with other conditions, making it challenging to differentiate and confirm a severe asthma diagnosis. That’s why clinicians must be competent in accurately diagnosing severe asthma and distinguishing severe asthma from its mimickers.

There's been an emergence of novel therapies for the treatment of severe asthma, including biologics targeting inflammatory pathways. These therapeutic options have ushered in a new era of personalized asthma management, which is why clinicians must be able to identify which patients are most likely to respond to newer biologic agents and need to be knowledgeable of the biologic and physiologic markers that form the basis for selecting a treatment.